**Core tip:** We have presented different surveys showing the resistance of *Helicobacter pylori* (*H. pylori*) to furazolidone from Asia and South America. The resistance rates varied but were mostly low (\< 5%). *H. pylori* mutations occurring in the *oorD* gene, including A041G, A122G, C349A(G), A78G, A112G, A335G, C156T and C165T, and in the *porD* gene, including G353A, A356G, C357T, C347T, C347G and C346A, have been indicated to be possibly related to the observed resistance. Regarding levofloxacin resistance, compound mutations of N87A, A88N and V65I at codon Asn-87 were recently observed in the *gyrA* gene for the first time.

TO THE EDITOR
=============

We have read with great interest the valuable article by Arslan et al\[[@B1]\], titled "Importance of antimicrobial susceptibility testing for the management of eradication in *Helicobacter pylori* infection". One of the main subjects of the review was the description of the resistance rates of different antibiotics and the potential mechanisms leading to decreased in *Helicobacter pylori* (*H. pylori*) antimicrobial susceptibility. However, the authors should consider clarifying two important issues.

The authors did not allude to the status of *H. pylori* treatment with furazolidone and the resistance to this antibiotic. We have provided existing surveys reporting the resistance of *H. pylori* to furazolidone in Table [1](#T1){ref-type="table"}. The resistance rates have been mostly reported to be lower than 5%; however, these rates can vary geographically. Furazolidone is not used widely in the United States and Europe; therefore, there are not enough data on its efficacy and resistance in these regions.

###### 

Studies evaluating the *Helicobacter pylori* resistance to furazolidone

  **Continent**                     **Country**                  **Study year**   **Strains (*n*)**                  **Method**      **Resistance (%)**           **Author**
  --------------------------------- ---------------------------- ---------------- ---------------------------------- --------------- ---------------------------- --------------------------
  Asia                              China (Shanghai)             2000-2009        293                                Agar dilution   0                            Sun et al\[[@B6]\]
  China (Zhejiang)                  2010-2012                    21               Agar dilution                      0.1             Su et al\[[@B7]\]            
  China (Zhejiang)                  2009-2014                    9687             Agar dilution                      \< 0.01         Ji et al\[[@B8]\]            
  India (Ghaziabad and New Delhi)   NA                           68               Agar dilution                      22.1            Gehlot et al\[[@B9]\]        
  India (Gujarat)                   2008-2011                    80               Disk diffusion                     13.8            Pandya et al\[[@B10]\]       
  Iran (Rasht)                      2012-2014                    169              Disk diffusion                     61.9            Maleknejad et al\[[@B11]\]   
  Iran (Shiraz)                     2004-2005                    106              Agar dilution                      9.4             Kohanteb et al\[[@B12]\]     
  Iran (Sari)                       2009                         197              Disk diffusion                     61.4            Abadi et al\[[@B13]\]        
  Iran (Tehran)                     2001-2004                    135              Disk diffusion                     0               Siavoshi et al\[[@B14]\]     
  Iran (Tehran)                     2002-2003                    24               Disk diffusion                     0               Fallahi et al\[[@B15]\]      
  Iran (Tehran)                     2005-2008                    110              Disk diffusion                     4.5             Siavoshi et al\[[@B16]\]     
  Iran (Tehran)                     2007-2008                    104              Disk diffusion                     0               Sirous et al\[[@B17]\]       
  Iran                              2003-2005                    100              Disk diffusion                     9               Rafeey et al\[[@B18]\]       
  South Korea                       1994-1999                    220              Agar dilution                      1.4             Kim et al\[[@B19]\]          
  Malaysia (Malacca)                2009                         90               Epsilometer test                   0               Goh et al\[[@B20]\]          
  Pakistan (Karachi)                2008-2013                    93               disk diffusion                     4.3             Siddiqui et al\[[@B21]\]     
  South America                     Brazil (Bragança Paulista)   NA               90                                 Agar dilution   4                            Mendonça et al\[[@B22]\]
  Brazil (Bragança Paulista)        NA                           138              Agar dilution                      13              Godoy et al\[[@B23]\]        
  Brazil (Sao Paulo)                NA                           39               Agar dilution                      0               Eisig et al\[[@B24]\]        
  Brazil (Sao Paulo)                2008-2009                    77               Agar dilution and disk diffusion   0               Ogata et al\[[@B25]\]        
  Brazil (Sao Paulo)                2008-2009                    77               Agar dilution                      0               Ogata et al\[[@B26]\]        

One of the main reasons for the emergence of resistance is related to the extensive use of furazolidone. In addition, regarding the molecular mechanisms, some genetic mutations have been identified. Mutations occurring in the *2-oxoglutarate:acceptor oxidoreductase* (*oorD*) gene, including *A041G*, *A122G*, *C349A(G)*, *A78G*, *A112G*, *A335G*, *C156T* and *C165T*, and in the *pyruvate oxidoreductase* (*porD*) gene, including *G353A*, *A356G*, *C357T*, *C347T*, *C347G* and *C346A*, are possibly related to the resistance\[[@B2],[@B3]\]. *The oor and por* genes are involved in the generation of acetyl coenzyme A (acetyl-CoA) and succinyl-CoA\[[@B4]\]. Despite these findings, additional molecular methods are proposed to reach a better understanding of the mechanisms that were mentioned.

Arslan et al\[[@B1]\] accurately documented the mechanism of levofloxacin resistance; *i.e*., point mutations in the *gyrA* (DNA *gyrase*) gene were stated to be potentially linked to the resistance. However, to complete their statement, it should be noted that compound mutations of N87A, A88N and V65I at codon Asn-87 were recently observed in the *gyrA* gene for the first time. L45F, A55S, A97V, D91N, R130K and G60S are other possible mutations that need to be assessed in studies with broader sample bases\[[@B5]\].
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